Efficiency of metabolic therapy in the mother-fetus system and offspring in hypoxic states in the experiment


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To carry out experiments to study of eltacin as an agent to prevent and protect a mother rat, its fetus and offspring from hypoxic damages. Material and methods. Experiments were carried out in 66 pregnant outbred albino rats, their fetuses and offspring; to model various hypoxic states, the female rats were given an aqueous solution of eltacin at a dose of 6 mg/kg per os at 16 to 20 days of pregnancy. Results. Models of the perfused rat heart, acute and chronic hemic hypoxia, resistance to acute hypoxia in female rats and their offspring when increasing altitude, and anoxia of an isolated fetus have shown that eltacin has pronounced antihypoxic properties in the mother rat, its fetus and offspring in case of oxygen deficiency. Conclusion. The experiments have demonstrated that eltacin as part of combination therapy is a promising energizing antihypoxant in obstetric practice.

Full Text

Restricted Access

About the authors

Galina A. Sheveleva

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: shewelewa.gal@yandex.ru
Sc.D., Consultant, Department of Immunology and Transfusion blood harvesting

Tatyana A. Fedorova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: tfedorova1@mail.ru
Doctor of Medical Sciences, Professor, Head of the Department of Transfusion and extracorporeal blood correction

Elena M. Chirkova

Research Institute of Cytochemistry and Molecular Biology

PhD, Senior Researcher

Yaroslav R. Nartsissov

Research Institute of Cytochemistry and Molecular Biology

Email: yarosl@biotic.dol.ru
Candidate of Physical and Mathematical Sciences, associate professor, head of the department of mathematical modeling and statistical analysis

Gennady I. Podoprigora

Research Institute of Cytochemistry and Molecular Biology

Email: gipodoprigora@yandex.ru
Doctor of Medical Sciences, professor, member of RAMTS, director

References

  1. Коноводова Е.Н., Бурлев Е.А. Железодефицитные состояния у беременных и родильниц. Акушерство и гинекология. 2012; 1: 137-42. [Konovodova E.N., Burlev V.A. Iron-deficiency states in pregnant women and puerperas. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2012; 1: 137-42. (in Russian)]
  2. Нарциссов Я.Р., Максимов М.Л., Максимова Л.Н. Метаболитная терапия как составная часть комплексного лечения хронических заболеваний. Русский медицинский журнал. 2016; 24(14): 894-900. [Nartsissov Ya.R., Maksimov M.L., Maksimova L.N. Metabolite therapy as part of comprehensive treatment of chronic diseases. Russkiy meditsinskiy zhurnal. 2016; 24(14): 894-900. (in Russian)]
  3. Селин А.А., Лобышева Н.В., Воронцова О.Н., Тоньшин А.А., Ягужинский Л.С., Нарциссов Я.Р. Механизм действия глицина как протектора нарушений энергетики тканей мозга в условиях гипоксии. Бюллетень экспериментальной биологии и медицины. 2012; 153(1): 52-5. [Selin A.A., Lobyisheva N.V., Vorontsova O.N., Tonshin A.A., Yaguzhinskiy L.S., Nartsissov Ya.R. The mechanism of action of glycine as a protector power disturbances in brain tissue hypoxia. Byulleten eksperimentalnoy biologii i meditsinyi. 2012; 153(1): 52-5. (in Russian)]
  4. Petrat F., Boengler K., Schulz R., de Groot H. Glycine, a simple physiological compound protecting by yet puzzling mechanism(s) against ischemia-reperfusion injury: current knowledge. Br. J. Pharmacol. 2012; 165(7): 2059-72.
  5. Максимова Л.Н., Заславская Р.М., Калинина Е.В., Нарциссов Я.Р. Клинический опыт применения оригинального метаболического препарата Элтацин у больных с хронической сердечной недостаточностью. Эффективная фармакотерапия. 2011; 16: 40-3. [Maksimova L.N., Zaslavskaya R.M., Kalinina E.V., Nartsissov Ya.R. Clinical experience with the original metabolic drug Eltatsin in patients with chronic heart failure. Effektivnaya farmakoterapiya. 2011; 16: 40-3. (in Russian)]
  6. Заславская Р.М., Лилица Г.В., Калинина Е.В., Комиссарова И.А., Максимова Л.М. Влияние метаболического препарата элтацин на клинические, функциональные и биохимические показатели у больных хронической сердечной недостаточностью. Рациональная фармакотерапия в кардиологии. 2007; 3(1): 33-6. [Zaslavskaya R.M., Lilitsa G.V., Kalinina E.V., Komissarova I.A., Maksimova L.M. Effect of metabolic eltatsin drug on clinical, functional and biochemical parameters in patients with chronic heart failure. Ratsionalnaya farmakoterapiya v kardiologii. 2007; 3(1): 33-6. (in Russian)]
  7. Максимова Л.Н., Максимов М.Л., Нарциссов Я.Р., Заславская Р.М., Калинина Е.В. Роль метаболитной терапии в лечении хронической сердечной недостаточности. Рациональная фармакотерапия в кардиологии. 2013; 9(5): 577-81. [Maksimova L.N., Maksimov M.L., Nartsissov Ya.R., Zaslavskaya R.M., Kalinina E.V. Metabolitic role of therapy in the treatment of chronic heart failure. Ratsionalnaya farmakoterapiya v kardiologii. 2013; 9(5): 577-81. (in Russian)]
  8. Лаврентьева О.В., Воронина Л.П., Татжикова К.А. Медикаментозная коррекция нарушений в системе свободнорадикальное окисление - антиоксидантная защита у больных бронхиальной астмой. Сибирский медицинский журнал (Иркутск). 2009; 84(1): 51-3. [Lavrenteva O.V., Voronina L.P., Tatzhikova K.A. Drug correction of the system free radical oxidation - antioxidant defense in patients with bronchial asthma. Sibirskiy meditsinskiy zhurnal (Irkutsk). 2009; 84(1): 51-3. (in Russian)]
  9. Кукес В., Жестовская А., Нарциссов Я., Тюкина Е., Шешегова Е. Метаболические препараты при лечении алкоголизма и различных заболеваний центральной нервной системы. Врач. 2016; 3: 25-8. [Kukes V., Zhestovskaya A., Nartsissov Ya., Tyukina E., Sheshegova E. Metabolic drugs in the treatment of alcoholism and various diseases of the central nervous system. Vrach. 2016; 3: 25-8. (in Russian)]
  10. Макарова Л.М. Оценка антигипоксической активности глицина и его фосфолирированного производного. Экспериментальная и клиническая фармакология. 2006; 69(3): 71-3. [Makarova L.M. Evaluation anti hypoxic activity of glycine and its phosphorilyc derivative. Eksperimentalnaya i klinicheskaya farmakologiya. 2006; 69(3): 71-3. (in Russian)]
  11. Корнеев А.А., Шевелева Г.А. Некоторые аспекты использования перфузируемого сердца крысы как модели для отбора антигипоксических соединений. Фармакология и токсикология. 1991; 3: 67-70. [Korneev A.A., Sheveleva G.A. Some aspects of the use of perfused rat heart as a model for screening compounds antihypoxic. Farmakologiya i toksikologiya. 1991; 3: 67-70. (in Russian)]
  12. Langendorff O. Untersuchungen am uberlebenden saugethierzen. Arch. Ges. Physiol. 1985; 61: 291.
  13. Neely J.R., Liebermeister N., Battersby T.J., Morgan N.E. Effects of pressur development on oxygen consumption by isolated rat heart. Am. J. Physiol. 1967; 212(4): 804.
  14. Purshottam T., Chosh N.C. Effect of acetauolamide (Diamox) at differente levels on survival time of rats under acute hypoxia and on Na+, K+ - ATP-ase activity of rat tissues microsomes. Aerospace Med. 1972; 43(6): 610.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies